Wall Street analysts predict that Imv Inc (NYSE:IMV) will report earnings per share of ($0.11) for the current fiscal quarter, Zacks reports. Zero analysts have made estimates for IMV’s earnings, with estimates ranging from ($0.12) to ($0.10). IMV posted earnings per share of ($0.06) in the same quarter last year, which indicates a negative year over year growth rate of 83.3%. The company is scheduled to issue its next earnings report on Monday, May 13th.
According to Zacks, analysts expect that IMV will report full-year earnings of ($0.42) per share for the current fiscal year, with EPS estimates ranging from ($0.47) to ($0.36). For the next fiscal year, analysts forecast that the business will post earnings of ($0.30) per share, with EPS estimates ranging from ($0.38) to ($0.12). Zacks’ earnings per share calculations are an average based on a survey of analysts that cover IMV.
IMV (NYSE:IMV) last issued its earnings results on Thursday, March 21st. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.07) by ($0.06). The company had revenue of $0.10 million for the quarter.
IMV stock traded down $0.18 on Wednesday, hitting $3.56. The company had a trading volume of 9,952 shares, compared to its average volume of 27,501. IMV has a 12-month low of $2.90 and a 12-month high of $7.21.
Institutional investors have recently modified their holdings of the company. Ipswich Investment Management Co. Inc. purchased a new position in shares of IMV during the 4th quarter worth $34,000. Hartford Financial Management Inc. boosted its stake in shares of IMV by 15.0% during the 4th quarter. Hartford Financial Management Inc. now owns 26,850 shares of the company’s stock worth $139,000 after acquiring an additional 3,500 shares during the last quarter. First Manhattan Co. boosted its stake in shares of IMV by 75.7% during the 1st quarter. First Manhattan Co. now owns 154,518 shares of the company’s stock worth $620,000 after acquiring an additional 66,550 shares during the last quarter. Finally, Ruffer LLP purchased a new position in shares of IMV during the 4th quarter worth $31,305,000.
IMV, Inc is a clinical-stage biopharmaceutical company, which engages in the development of cancer immunotherapies and infectious disease vaccines. The firm’s patented platform, DepoVax, provides controlled and prolonged exposure of antigens and adjuvant to the immune system. The company was founded by Warwick Kimmins and Brian Lowe on March 28, 2000 and is headquartered in Halifax, Canada.
Featured Story: What is Cost of Debt?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for IMV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMV and related companies with MarketBeat.com's FREE daily email newsletter.